Irie K, Yasutake K, Imamura Y, Yoshimura Y, Nakamura T, Yoshida M, Fujisawa T, Nishimura S, Mizogami H, Sawada Y
Gan To Kagaku Ryoho. 1986 May;13(5):1893-6.
An SF-SP Tegafur spansule preparation was administered to 26 patients with advanced cancer (24 evaluable), and the clinical effectiveness and toxicity were studied. In most of cases, daily dosages of 800 mg were administered in two parts, in a few cases, daily dosages of 1,000 mg or 1,200 mg were given. Clinical effectiveness: The evaluation of effectiveness was based on the Koyama-Saito group criteria. Of the 24 evaluable cases, PR was observed in 3 cases of gastric cancer, one of colon cancer, and one of liver cancer, a total of 5 cases (20.8%). In these 5 cases the daily dosage was 800 mg, and the median duration of PR was 51 days.
TOXICITY was observed in 3 (11.5%) of the 26 cases.
对26例晚期癌症患者（24例可评估）给予丝裂霉素-替加氟长效胶囊制剂，并研究其临床疗效和毒性。大多数情况下，每日剂量800毫克分两次给药，少数情况下，每日剂量为1000毫克或1200毫克。临床疗效：疗效评估基于小山-斋藤组标准。在24例可评估病例中，3例胃癌、1例结肠癌和1例肝癌观察到部分缓解（PR），共5例（20.8%）。这5例患者的每日剂量为800毫克，PR的中位持续时间为51天。
26例中有3例（11.5%）观察到毒性反应。
